DOCSLIB.ORG

Understanding the NMR Lipoprofile® Test Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Understanding the NMR Lipoprofile® Test Report The NMR LipoProfile ® test may be covered 1447 York Court by one or more issued or pending patents, Burlington, NC 27215 including U.S. Patent Nos. 6,518,069; 800-788-9223 The6,576,471; NMR LipoProfile 6,653,140; ® and test 7,243,030. may be covered www.labcorp.com1447 York Court CLIA: 34D0655059 Medical Director: William F Hancock, MD Theby one NMR or moreLipoProfile issued ® or test pending may be patents, covered Burlington,1447 YNCork 27215 Court byincludingPatient one or Name U.S.more Patent issued Nos. or pending 6,518,069; patents, Gender Age Burlington,800-788-9223Page NC 27215 1 of 2 including6,576,471;SAMPLE U.S. 6,653,140;REPOR PatentT, Nos.123810 and 6,518,069;7,243,030. F 57 Account Information www.labcorp.com800-788-9223 6,576,471;CLIA: 34D0655059 6,653,140; and 7,243,030. Account # Medical Director: Williamwww.labcorp.com F Hancock, MD Physician Information Medical Director: William F Hancock, MD CLIA:Patient 34D0655059 Name Gender Age Test Account Page 1 of 2 3060 South Church Street PatientSAMPLE Name REPORT, 123810 GenderFAge 57 Account Information Page 1 of 2 Patient ID DOB Specimen ID Burlington, NC 27215 SAMPLE REPORT, 123810 F 57 Account # Account Information Physician Information Phone: (336) 436-8645 Fax: (336) 436-8645 AccountTest Account # Physician Information Date Collected Date Entered Date Reported T3060est Account SouthControl Church Number Street Fasting Patient07/17/2015 ID 07/21/2015DOB 07/21/2015Specimen 2:03ID PM 3060Burlington, South NC Church 27215 Street NO Patient ID DOB Specimen ID Burlington,Phone: (336) NC 436-8645 27215 Fax: (336) 436-8645 Phone: (336) 436-8645 Fax: (336) 436-8645 DateNMR Collected LipoProfile Date ® testEntered Date Reported ReferenceControl Range Number¹ Fasting Understanding the NMR LipoProfile®Date07/17/2015 Collected Test Report Date07/21/2015 Entered 07/21/2015Date Reported 2:03 PM Control Number FastingNO 07/17/2015 07/21/2015Percentile¹ 07/21/201520th 2:03 PM 50th 80th 95th NO LDL-P NMR LipoProfile nmoI/L® test Low ModerateReference Borderline Range¹ High Very High • LDL-P is the direct measure of low density lipoprotein NMR LipoProfile ® test ReferenceHigh Range¹ 1600 Percentile¹ < 1000 20th 1000 - 1299 50th 1300 - 1599 80th 1600 - 2000 95th > 2000 particles - the causal link between high levels of LDL-P LDL-P 20th 50th 80th 95th (LDL Particle Number) nmoI/L Percentile¹ Low Moderate Borderline High Very High and development of cardiovascular disease (CVD) is well 1. Reference population (5,362 mennmoI/L and women) not on lipid mediLowcation enrolled in the ModerateMulti-Ethnic Study of Atherosclerosis BorderlineHigh (MESA). Mora, et al.High Atherosclerosis 2007. Very High established. LDL-P 1600 < 1000 1000 - 1299 1300High - 1599 1600 - 2000 > 2000 • Studies have demonstrated per-particle cholesterol amount (LDL Particle Number) 1600 < 1000 Near1000 or - Above1299 1300Borderline - 1599 1600 - 2000 > 2000 LipidsLDL-P mg/dL Optimal High Very High varies in patients with type II diabetes, statin-treated 1.(LDL Reference Particle population Number) (5,362 men and women) not on lipid medication enrolled in the Multi-EthnicOptimal Study of AtherosclerosisHigh (MESA). Mora, et al. Atherosclerosis 2007. patients, and those with cardiometabolic risk factors (CMR) LDL-C1. Reference population (5,362 men and90 women) not on lipid medi< cation100 enrolled in the Multi-Ethnic100 - 129 Study of Atherosclerosis130 - 159 (MESA). Mora,160 et al. -Atherosclerosis 189 2007. ≥ 190 1,2,3 (calculated) listed below: Near or Above Borderline 4 Lipids mg/dL Optimal High Very High Age: men ≥45 yrs, women ≥ 55 yrs) NearOptimal or Above BorderlineHigh Lipids mg/dL Optimal High Very High Elevated BP: (≥130/≥85 mmHg; on antihypertensive LDL-C mg/dL90 < 100 100Optimal - 129mg/dL 130High - 159 160 - 189 mg/dL≥ 190 medication)5 LDL-C(calculated) 90 < 100 100 - 129 130 - 159 160 - 189 ≥ 190 (calculated)HDL-C 48 Triglycerides 78 Total Cholesterol 198 Abdominal obesity/waist circumference: MANAGINGDesirable ≥ TO40 AN LDL-P GOALDesirable CAN < 150 BE ACCOMPLISHEDDesirable < 200 male ≥ 40” (Asian ≥ 35”), female ≥ 35” (Asian ≥ 31”)5 mg/dL mg/dL mg/dL LDL-C is inaccurate if patient is non-fasting. WITHIN EXISTINGmg/dL THERAPEUTIC STRATEGIESmg/dL AND GUIDELINESmg/dL Elevated triglycerides: (≥150 mg/dL), low HDL HDL-C 48 Triglycerides 78 Total Cholesterol 198 (men < 40 mg/dL, women < 50 mg/dL), increased HistoricalHDL-C ReportingDesirable48 ≥ 40 Triglycerides Desirable78 < 150 Total Cholesterol Desirable198 < 200 2,5 numbers of small dense LDL particles, on drug LDL-C is inaccurate if patient is non-fasting. • OutcomeDesirable study data ≥ 40 has shown when measures ofDesirable < LDL-P150 and LDL-C Discordance inDesirable MESA 14< 200 treatment for elevated triglycerides or HDL-C LDL-C is inaccurate if patient is non-fasting. 5 LDL-C and LDL-P agree (concordance), risk factor Relationship with Incident CVD Events (n=319) Elevated fasting blood glucose: (≥ 100 mg/dL), on HistoricalLDL-P Reporting drug treatment for elevated glucose Historicalprofiles Reporting are favorable. However when LDL-C and 2 Insulin resistance: (IR) LDL-P disagree (discordance), CVD risk tracks with 9 ►1600 (07/17/2015) • Many expert panels recommend use of LDL-P values to LDL-P LDL-P or Apo B. optimize treatment decisions in these at-risk patients.2,6 LDL-P • Since LDL-C may be an unreliable measure in • NMR LipoProfile® Test is FDA cleared for use in conjunction ►1600 (07/17/2015) with other lipid measurements and clinical evaluation to aid patients with type II diabetes, statin-treated ►1600 (07/17/2015) in the management of lipoprotein disorders associated patients, and those with CMR factor due to 7 per-particle cholesterol variability, expert panels with CVD. LDL-C recommend use of LDL-P or Apo B to optimize treatment decisions in these patients.4,5,8,11,12,13 Lipids ►90 (07/17/2015) LDL-C • Traditional lipid panel includes LDL-C, HDL-C, triglycerides LDL-C and total cholesterol. ►90 (07/17/2015) • Whether calculated or measured directly, LDL-C is an Personalized LDL Management►90 (07/17/2015) estimate of the amount of cholesterol contained within Targets of Therapy (Adapted with permission from International Guidelines Center2) 1 This document contains private and confidential health information protected by state and © 1995-2015 Laboratory Corporation of America® Holdings LDL-P. HIGH federal law. If you have received this documentLOW in error, please call 800-222-7566. BORDERLINE All Rights Reserved - Enterprise Report Version: 1.00 LDL-P 1000 1300 This document containsranges private* and confidential health information protected by state and © 1995-2015 Laboratory Corporation of America® Holdings federal law. If you (nmol/L):have received this document in error, please call . All Rights Reserved - Enterprise Report Version: 1.00 Historical Reporting This document contains private and confidential health information protected800-222-7566 by state and © 1995-2015 Laboratory Corporation of America® Holdings Patient LDL-P and LDL-C values and dates of services are federal law. If you have received this documentTarget infor error, high–risk please callpatients 800-222-7566. Target for moderate-risk patientsAll Rights Reserved - Enterprise Report Version: 1.00 tracked over time, providing opportunities for clinician/patient LDL-C discussions regarding treatment strategies ranges* 100 130 (mg/dL): Reduce LDL Particle Production By: Improve LDL Particle Clearance By: • Diet • Exercise • Weight Loss • More potent Statins 35% to 55% LDL-P • Glycemic Control • Gut agents • Marine Omega-3 Ezetimibe - 15% to 25% LDL-P DHA + EPA - no consistent effect on LDL-P Resins/Bile Acid Sequestrants - 15% to 30% LDL-P EPA Only - 4% to 15% LDL-P • Statin + Gut, Statin + Niacin 50% to 70% LDL-P • Statin + Gut + Niacin >60% LDL-P The NMR LipoProfile ® test may be covered 1447 York Court by one or more issued or pending patents, Burlington, NC 27215 including U.S. Patent Nos. 6,518,069; 800-788-9223 6,576,471; 6,653,140; and 7,243,030. www.labcorp.com1447 York Court CLIA: 34D0655059 Medical Director: WilliamBurlington, F Hancock, NC 27215 MD 800-788-9223 Patient Name Gender Age Page 2 of 2 Medical Director: William F Hancock, MD SAMPLE REPORT, 123810 F 57 Specimen Number Patient ID Account Number AccountAccount Information Phone Account Fax Account # Physician300-001-0094-0 Information 90000999 (336) 436-8645 (336) 436-8645 Patient Last Name Patient First Name Test Account Account Address SAMPLE REPORT 123638 3060 SouthLabCorp Church Test Street Master Test Account PatientAge ID Date of Birth DOBSex SpecimenFasting ID Burlington, NC 27215 00 N/A NOT SPECIFIED 3060 South Church Street Phone: (336) 436-8645 Fax: 1447(336) York 436-8645 Court Control Number NPI Burlington, NC 27215 Burlington, NC 27215 Understanding the NMR LipoProfile®Date Collected Test Report Date Entered Date Reported Control Number Fasting Date Collected Date Entered Date and Time Reported Physician ID & Name Page Number 07/17/2015 07/21/2015 07/21/2015 2:03 PM 800-788-9223NO 10/25/2015 10/26/2015 11/13/2015 11:48 AM ET Medical Director: William 2F Hancock,of 2 MD PARTICLESpecimen CONCENTRATION Number AND SIZEPatient ID Account Number Account Phone Account Fax LDL and HDL Particles PARTICLE300-001-0094-0 CONCENTRATION AND SIZE 90000999 (336) 436-8645 (336) 436-8645 Lower CVD Risk Higher CVD Risk Patient Last Name Patient First Name Account Address • HDL-P is the direct measure of high density lipoprotein LDL and HDL Particles Lower CVD Risk Higher CVD Risk SAMPLE
Load more

Recommended publications
  • Lrp1 Modulators
    Last updated on February 14, 2021 Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer’s Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in- development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models. Lrp1 Modulators Evidence Summary Lrp1 has a variety of essential functions, mediated by a diverse array of ligands. Therapeutics will need to target specific interactions. Neuroprotective Benefit: Lrp1-mediated interactions promote Aβ clearance, Aβ generation, tau propagation, brain glucose utilization, and brain lipid homeostasis. The therapeutic effect will depend on the interaction targeted. Aging and related health concerns: Lrp1 plays mixed roles in cardiovascular diseases and cancer, dependent on context. Lrp1 is dysregulated in metabolic disease, which may contribute to insulin resistance. Safety: Broad-spectrum Lrp1 modulators are untenable therapeutics due to the high potential for extensive side effects. Therapies that target a specific Lrp1-ligand interaction are expected to have a better therapeutic profile. 1 Last updated on February 14, 2021 Availability: Research use Dose: N/A Chemical formula: N/A S16 is in clinical trials MW: N/A Half life: N/A BBB: Angiopep is a peptide that facilitates BBB penetrance by interacting with Lrp1 Clinical trials: S16, an Lrp1 Observational studies: sLrp1 levels are agonist was tested in healthy altered in Alzheimer’s disease, volunteers (n=10) in a Phase 1 cardiovascular disease, and metabolic study.
    [Show full text]
  • Elevated Lipoprotein (A) Patient-Centered Education from the National Lipid Association
    Elevated Lipoprotein (a) Patient-Centered Education From the National Lipid Association What is Elevated Lipoprotein (a) ? Apo-B Apo (a) Lipoprotein (a) is a form of Low Density Lipoprotein (LDL) in which another protein, called Apo(a), is attached to each LDL particle as it carries cholesterol around in the body. Having elevated blood levels of Lipoprotein (a) raises a person’s risk of heart attack and stroke beyond what is normally seen from elevated LDL cholesterol alone. This is believed to be due to the Apo(a) protein, which may reduce the body’s ability to break down clots. Elevated Lipoprotein (a) is usually inherited from one parent. About 1 in 4 people in the population are believed to have elevated blood levels of Lipoprotein (a). African Americans may have higher levels. Besides genetics, Lipoprotein (a) levels may result from increased intake of some types of fats, and some medical conditions. Treatment of elevated Lipoprotein (a) is based on a person’s risk of heart attack or stroke. A healthy diet and lifestyle are the first step to reducing heart attack and stroke risk from elevated Lipoprotein (a). Medications also may help. ‘ Statins’ do not lower Lipoprotein (a) levels. However, statins are the most used medication for lowering heart attack and stroke risk in general, and so they are the most used medicine to treat risk from elevated Lipoprotein (a). Niacin can lower Lipoprotein (a) levels by 25-40%, as can PCSK9 inhibitors, but both are used less often. A new medication for lowering Lipoprotein (a) is being tested.
    [Show full text]
  • Increased Prebeta-High Density Lipoprotein, Apolipoprotein AI, And
    Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. X Jiang, … , J L Breslow, A R Tall J Clin Invest. 1996;98(10):2373-2380. https://doi.org/10.1172/JCI119050. Research Article Human plasma phospholipid transfer protein (PLTP) circulates bound to high density lipoprotein (HDL) and mediates both net transfer and exchange of phospholipids between different lipoproteins. However, its overall function in lipoprotein metabolism is unknown. To assess the effects of increased plasma levels of PLTP, human PLTP transgenic mice were established using the human PLTP gene driven by its natural promoter. One line of PLTP transgenic mice with moderate expression of PLTP mRNA and protein was obtained. The order of human PLTP mRNA expression in tissues was: liver, kidney, brain, small intestine > lung > spleen > heart, adipose tissue. Western blotting using a human PLTP monoclonal antibody revealed authentic human PLTP (Mr 80 kD) in plasma. Plasma PLTP activity was increased by 29% in PLTP transgenic mice. However, plasma lipoprotein analysis, comparing PLTP transgenic mice to control littermates, revealed no significant changes in the plasma lipoprotein lipids or apolipoproteins. Since previous studies have shown that human cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase only function optimally in human apoAI transgenic mice, the human PLTP transgenic mice were cross-bred with human apoAI transgenic mice. In the human apoAI transgenic background, PLTP expression resulted in increased PLTP activity (47%), HDL phospholipid (26%), cholesteryl ester (24%), free cholesterol (37%), and apoAI (22%). There was a major increase of apoAI in prebeta-HDL (56%) and […] Find the latest version: https://jci.me/119050/pdf Increased Pre␤-high Density Lipoprotein, Apolipoprotein AI, and Phospholipid in Mice Expressing the Human Phospholipid Transfer Protein and Human Apolipoprotein AI Transgenes Xian-cheng Jiang,* Omar L.
    [Show full text]
  • Handout 11 Lipoprotein Metabolism
    Handout 11 Lipoprotein Metabolism ANSC/NUTR 618 LIPIDS & LIPID METABOLISM Lipoprotein Metabolism I. Chylomicrons (exogenous pathway) A. 83% triacylglycerol, 2% protein, 8% cholesterol plus cholesterol esters, 7% phospholipid (esp. phosphatidylcholine) B. Secreted as nascent chylomicrons from mucosal cells with ApoB48 and ApoA1 C. Acquire ApoC1, C2, and C3 in blood (from high-density lipoproteins) 1. ApoC1 activates lecithin:cholesterol acyltransferase (LCAT; in blood) and ApoC2 activates lipoprotein lipase. ApoC3 prevents uptake by the liver. 2. Required for conversion of chylomicrons to remnant particles. D. Triacylgycerols are removed from chylomicrons at extrahepatic tissues by lipoprotein lipase (LPL). E. Chylomicron remnants are taken up by the LDL-receptor-related protein (LRP). Exceptions: In birds, the lymphatic system is poorly developed. Instead, pro-microns are formed, which enter the hepatic portal system (like bile salts) and are transported directly to the liver. 1 Handout 11 Lipoprotein Metabolism Ruminants do not synthesis chylomicrons primarily due to low fat intake. Rather, their dietary fats are transported from the small intestine as very low-density lipoproteins. F. Lipoprotein lipase 1. Lipoprotein lipase is synthesized by various cells (e.g., adipose tissue, cardiac and skeletal muscle) and secreted to the capillary endothelial cells. a. LPL is bound to the endothelial cells by a heparin sulfate bond. b. LPL requires lipoproteins (i.e., apoC2) for activity, hence the name. 2. TAG within the chylomicrons and VLDL are hydrolyzed to NEFA, glycerol, and 2-MAG. a. NEFA and 2-MAG are taken up the tissues and reesterified to TAG b. Glycerol is taken up by the liver for metabolism and converted to G-3-P by glycerol kinase (not present in adipose tissue).
    [Show full text]
  • Apoe Lipidation As a Therapeutic Target in Alzheimer's Disease
    International Journal of Molecular Sciences Review ApoE Lipidation as a Therapeutic Target in Alzheimer’s Disease Maria Fe Lanfranco, Christi Anne Ng and G. William Rebeck * Department of Neuroscience, Georgetown University Medical Center, 3970 Reservoir Road NW, Washington, DC 20057, USA; [email protected] (M.F.L.); [email protected] (C.A.N.) * Correspondence: [email protected]; Tel.: +1-202-687-1534 Received: 6 August 2020; Accepted: 30 August 2020; Published: 1 September 2020 Abstract: Apolipoprotein E (APOE) is the major cholesterol carrier in the brain, affecting various normal cellular processes including neuronal growth, repair and remodeling of membranes, synaptogenesis, clearance and degradation of amyloid β (Aβ) and neuroinflammation. In humans, the APOE gene has three common allelic variants, termed E2, E3, and E4. APOE4 is considered the strongest genetic risk factor for Alzheimer’s disease (AD), whereas APOE2 is neuroprotective. To perform its normal functions, apoE must be secreted and properly lipidated, a process influenced by the structural differences associated with apoE isoforms. Here we highlight the importance of lipidated apoE as well as the APOE-lipidation targeted therapeutic approaches that have the potential to correct or prevent neurodegeneration. Many of these approaches have been validated using diverse cellular and animal models. Overall, there is great potential to improve the lipidated state of apoE with the goal of ameliorating APOE-associated central nervous system impairments. Keywords: apolipoprotein E; cholesterol; lipid homeostasis; neurodegeneration 1. Scope of This Review In this review, we will first consider the role of apolipoprotein E (apoE) in lipid homeostasis in the central nervous system (CNS).
    [Show full text]
  • The Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Mediates the Endocytosis of the Cellular Prion Protein David R Taylor, Nigel M Hooper
    The low-density lipoprotein receptor-related protein 1 (LRP1) mediates the endocytosis of the cellular prion protein David R Taylor, Nigel M Hooper To cite this version: David R Taylor, Nigel M Hooper. The low-density lipoprotein receptor-related protein 1 (LRP1) mediates the endocytosis of the cellular prion protein. Biochemical Journal, Portland Press, 2006, 402 (1), pp.17-23. 10.1042/BJ20061736. hal-00478699 HAL Id: hal-00478699 https://hal.archives-ouvertes.fr/hal-00478699 Submitted on 30 Apr 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Biochemical Journal Immediate Publication. Published on 8 Dec 2006 as manuscript BJ20061736 The low-density lipoprotein receptor-related protein 1 (LRP1) mediates the endocytosis of the cellular prion protein David R. Taylor and Nigel M. Hooper* Proteolysis Research Group Institute of Molecular and Cellular Biology Faculty of Biological Sciences and Leeds Institute of Genetics, Health and Therapeutics University of Leeds Leeds LS2 9JT UK * To whom correspondence should be addressed: tel. +44 113 343 3163; fax. +44 113 343 3167; e-mail: [email protected] Running title: LRP1 mediates the endocytosis of PrP Key words: amyloid precursor protein, copper, endocytosis, low-density lipoprotein receptor-related protein-1, prion, receptor associated protein.
    [Show full text]
  • Postprandial Lipoprotein Metabolism: VLDL Vs Chylomicrons
    UC Davis UC Davis Previously Published Works Title Postprandial lipoprotein metabolism: VLDL vs chylomicrons. Permalink https://escholarship.org/uc/item/9wx8p0x5 Journal Clinica chimica acta; international journal of clinical chemistry, 412(15-16) ISSN 0009-8981 Authors Nakajima, Katsuyuki Nakano, Takamitsu Tokita, Yoshiharu et al. Publication Date 2011-07-01 DOI 10.1016/j.cca.2011.04.018 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Clinica Chimica Acta 412 (2011) 1306–1318 Contents lists available at ScienceDirect Clinica Chimica Acta journal homepage: www.elsevier.com/locate/clinchim Invited critical review Postprandial lipoprotein metabolism: VLDL vs chylomicrons Katsuyuki Nakajima a,b,d,e,i,⁎, Takamitsu Nakano a,b, Yoshiharu Tokita a, Takeaki Nagamine a, Akihiro Inazu c, Junji Kobayashi d, Hiroshi Mabuchi d, Kimber L. Stanhope e, Peter J. Havel e, Mitsuyo Okazaki f,g, Masumi Ai h,i, Akira Tanaka g,i a School of Health Sciences, Faculty of Medicine, Gunma University, Maebashi, Gunma, Japan b Otsuka Pharmaceuticals Co., Ltd, Tokushima, Japan c Department of Laboratory Sciences, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan d Department of Lipidology and Division of Cardiology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan e Department of Molecular Biosciences, School of Veterinary Medicine and Department of Nutrition, University of California, Davis, CA, USA f Skylight Biotech Inc., Akita, Japan g Department of Vascular Medicine and
    [Show full text]
  • The Role of Low-Density Lipoprotein Receptor-Related Protein 1 in Lipid Metabolism, Glucose Homeostasis and Inflammation
    International Journal of Molecular Sciences Review The Role of Low-Density Lipoprotein Receptor-Related Protein 1 in Lipid Metabolism, Glucose Homeostasis and Inflammation Virginia Actis Dato 1,2 and Gustavo Alberto Chiabrando 1,2,* 1 Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba X5000HUA, Argentina; [email protected] 2 Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI), Córdoba X5000HUA, Argentina * Correspondence: [email protected]; Tel.: +54-351-4334264 (ext. 3431) Received: 6 May 2018; Accepted: 13 June 2018; Published: 15 June 2018 Abstract: Metabolic syndrome (MetS) is a highly prevalent disorder which can be used to identify individuals with a higher risk for cardiovascular disease and type 2 diabetes. This metabolic syndrome is characterized by a combination of physiological, metabolic, and molecular alterations such as insulin resistance, dyslipidemia, and central obesity. The low-density lipoprotein receptor-related protein 1 (LRP1—A member of the LDL receptor family) is an endocytic and signaling receptor that is expressed in several tissues. It is involved in the clearance of chylomicron remnants from circulation, and has been demonstrated to play a key role in the lipid metabolism at the hepatic level. Recent studies have shown that LRP1 is involved in insulin receptor (IR) trafficking and intracellular signaling activity, which have an impact on the regulation of glucose homeostasis in adipocytes, muscle cells, and brain. In addition, LRP1 has the potential to inhibit or sustain inflammation in macrophages, depending on its cellular expression, as well as the presence of particular types of ligands in the extracellular microenvironment.
    [Show full text]
  • ABCA1) in Human Disease
    International Journal of Molecular Sciences Review The Role of the ATP-Binding Cassette A1 (ABCA1) in Human Disease Leonor Jacobo-Albavera 1,† , Mayra Domínguez-Pérez 1,† , Diana Jhoseline Medina-Leyte 1,2 , Antonia González-Garrido 1 and Teresa Villarreal-Molina 1,* 1 Laboratorio de Genómica de Enfermedades Cardiovasculares, Dirección de Investigación, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City CP14610, Mexico; [email protected] (L.J.-A.); [email protected] (M.D.-P.); [email protected] (D.J.M.-L.); [email protected] (A.G.-G.) 2 Posgrado en Ciencias Biológicas, Universidad Nacional Autónoma de México (UNAM), Coyoacán, Mexico City CP04510, Mexico * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: Cholesterol homeostasis is essential in normal physiology of all cells. One of several proteins involved in cholesterol homeostasis is the ATP-binding cassette transporter A1 (ABCA1), a transmembrane protein widely expressed in many tissues. One of its main functions is the efflux of intracellular free cholesterol and phospholipids across the plasma membrane to combine with apolipoproteins, mainly apolipoprotein A-I (Apo A-I), forming nascent high-density lipoprotein- cholesterol (HDL-C) particles, the first step of reverse cholesterol transport (RCT). In addition, ABCA1 regulates cholesterol and phospholipid content in the plasma membrane affecting lipid rafts, microparticle (MP) formation and cell signaling. Thus, it is not surprising that impaired ABCA1 function and altered cholesterol homeostasis may affect many different organs and is involved in the Citation: Jacobo-Albavera, L.; pathophysiology of a broad array of diseases. This review describes evidence obtained from animal Domínguez-Pérez, M.; Medina-Leyte, models, human studies and genetic variation explaining how ABCA1 is involved in dyslipidemia, D.J.; González-Garrido, A.; Villarreal- coronary heart disease (CHD), type 2 diabetes (T2D), thrombosis, neurological disorders, age-related Molina, T.
    [Show full text]
  • Use of Lipoprotein(A) in Clinical Practice: a Biomarker Whose Time Has Come
    Journal of Clinical Lipidology (2019) -, -–- Original Research Use of lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. Don P. Wilson, MD, on behalf of the Writing group Don P. Wilson, MD*, Terry A. Jacobson, MD, Peter H. Jones, MD, Marlys L. Koschinsky, PhD, Catherine J. McNeal, MD, PhD, Børge G. Nordestgaard, MD, DMSc, Carl E. Orringer, MD Department of Pediatric Endocrinology and Diabetes, Cook Children’s Medical Center, Fort Worth, TX, USA (Dr Wilson); Department of Medicine, Lipid Clinic and Cardiovascular Risk Reduction Program, Emory University, Atlanta, GA, USA (Dr Jacobson); Department of Medicine, Baylor College of Medicine, Houston, TX, USA (Dr Jones); Robarts Research Institute, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada (Dr Koschinsky); Division of Cardiology, Department of Internal Medicine, Baylor Scott & White Health, Temple, TX, USA (Dr McNeal); Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark (Dr Nordestgaard); and Division of Cardiology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA (Dr Orringer) KEYWORDS: Abstract: Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic car- Lipoprotein (a); diovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observa- Lp(a); tional and genetic evidence strongly support a causal relationship between high plasma concentrations Biomarker; of Lp(a) and increased risk of atherosclerotic cardiovascular disease–related events, such as myocardial Atherosclerotic infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of cardiovascular disease; evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels Cutpoints; to inform treatment strategies in primary and secondary prevention.
    [Show full text]
  • The Importance of Lipoprotein Lipase Regulationin Atherosclerosis
    biomedicines Review The Importance of Lipoprotein Lipase Regulation in Atherosclerosis Anni Kumari 1,2 , Kristian K. Kristensen 1,2 , Michael Ploug 1,2 and Anne-Marie Lund Winther 1,2,* 1 Finsen Laboratory, Rigshospitalet, DK-2200 Copenhagen N, Denmark; Anni.Kumari@finsenlab.dk (A.K.); kristian.kristensen@finsenlab.dk (K.K.K.); m-ploug@finsenlab.dk (M.P.) 2 Biotech Research and Innovation Centre (BRIC), University of Copenhagen, DK-2200 Copenhagen N, Denmark * Correspondence: Anne.Marie@finsenlab.dk Abstract: Lipoprotein lipase (LPL) plays a major role in the lipid homeostasis mainly by mediating the intravascular lipolysis of triglyceride rich lipoproteins. Impaired LPL activity leads to the accumulation of chylomicrons and very low-density lipoproteins (VLDL) in plasma, resulting in hypertriglyceridemia. While low-density lipoprotein cholesterol (LDL-C) is recognized as a primary risk factor for atherosclerosis, hypertriglyceridemia has been shown to be an independent risk factor for cardiovascular disease (CVD) and a residual risk factor in atherosclerosis development. In this review, we focus on the lipolysis machinery and discuss the potential role of triglycerides, remnant particles, and lipolysis mediators in the onset and progression of atherosclerotic cardiovascular disease (ASCVD). This review details a number of important factors involved in the maturation and transportation of LPL to the capillaries, where the triglycerides are hydrolyzed, generating remnant lipoproteins. Moreover, LPL and other factors involved in intravascular lipolysis are also reported to impact the clearance of remnant lipoproteins from plasma and promote lipoprotein retention in Citation: Kumari, A.; Kristensen, capillaries. Apolipoproteins (Apo) and angiopoietin-like proteins (ANGPTLs) play a crucial role in K.K.; Ploug, M.; Winther, A.-M.L.
    [Show full text]
  • Clinical Feature: the Evolution of Lipid, Lipoprotein, and Apolipoprotein Markers of CVD Risk and Therapeutic Targets—Is It Ti
    Official Publication of the National Lipid Association LipidSpin Clinical Feature: The Evolution of Lipid, Lipoprotein, and Apolipoprotein Markers of CVD Risk and Therapeutic Targets—Is it Time to Abandon the Cholesterol Content of Atherogenic Lipoproteins? Also in this issue: “HDL-P vs. ApoA1 vs. HDL-C” in Context of the HDL-Hypothesis Controversy The Role of Remnant Lipoproteins in Atherogenesis This issue sponsored by the Pacific Lipid Association Volume 11 Issue 2 Spring 2013 visit www.lipid.org In This Issue: Spring 2013 (Volume 11, Issue 2) Editors 2 From the NLA President JAMES A. UNDERBERG, MD, MS, FACPM, FACP, FNLA* Our Pursuit Continues Preventive CV Medicine, Lipidology and Hypertension —Peter P. Toth, MD, PhD, FNLA* Clinical Assistant Professor of Medicine NYU Medical School and Center for CV Prevention New York, NY 3 From the PLA President Look for the NLA Community logo to discuss articles online at www.lipid.org ROBERT A. WILD, MD, PhD, MPH, FNLA* Apolipoproteins in Clinical Practice Clinical Epidemiology and Biostatistics and —J. Antonio G. López, MD, FNLA Clinical Lipidology Professor Oklahoma University Health Sciences Center Letter from the Lipid Spin Editors Oklahoma City, OK 4 27 Practical Pearls The Times They Are A-changin’ Cardiac Auscultation for the Managing Editor —Robert A. Wild, MD, PhD, FNLA* MEGAN L. SEERY Lipidologist: A Systolic Murmur You National Lipid Association Do Not Want to Miss! 5 Clinical Feature —J. Antonio G. López, MD, FNLA* Executive Director CHRISTOPHER R. SEYMOUR, MBA Is it Time to Abandon the —John R. Nelson, MD, FNLA* National Lipid Association Cholesterol Content of Atherogenic Contributing Editor Lipoproteins? 30 Case Study KEVIN C.
    [Show full text]